gc012f
gracell biotechnologies
['nhl', 'gc012f ', 'lymphoma', 'lymsm']
congress|#eha2023 yi zhang, zhengzhou university hospital presents results from the first-in-human study of cd19/bcma dual cart gc012f for r/r b-nhl. the longest duration of remission was 14.4 months and no dose-limiting toxicities were recorded #lymphoma #lymsm #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm